Europe Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Jul 2019
  • Europe
  • 350 Pages
  • No of Tables: 224
  • No of Figures: 27

Europe Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe)  – Industry Trends and Forecast to 2026

Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).

Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.

Segmentation: Europe Anticoagulation Therapy Market

Europe anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.

  • On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
  • On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
  • On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
  • On the basis of route of administration, the market is segmented into oral and injectable
  • On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
  • On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
  • On the basis of type, the market is segmented into generics and branded
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

Competitive Analysis: Europe Anticoagulation Therapy Market

Some of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.

Recent Developments

  • In September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD). This will attract the potential consumers helping in the growth of the company.
  • In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg. It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD). This approval will help the company to develop anticoagulant business in European countries.
  • In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban). It is a branded version of edoxaban. It is developed to reduce chances of stroke and systemic embolism (SE) in patients having non-valvular atrial fibrillation (NVAF). This product approval will help to expand Daiichi’s product portfolio in Europe as company can market it in to all European States.

Research Methodology: Europe Anticoagulation Therapy Market

Primary Rependants:

Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.


SKU-

TABLE 1 AGEING WORLD POPULATION

TABLE 2 POSTOPERATIVE PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS IN HIP AND KNEE SURGERIES, 2015

TABLE 3 EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 4 EUROPE DEEP VEIN THROMBOSIS (DVT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 5 EUROPE PULMONARY EMBOLISM (PE) IN ANTICOAGULATION THERAPY MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 6 EUROPE ARTERIAL THROMBOEMBOLISM (AT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 EUROPE STROKE IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 8 EUROPE OTHERS IN EUROPE ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 9 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 10 EUROPE NOVEL ORAL ANTICOAGUALTANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 12 EUROPE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 13 EUROPE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 14 EUROPE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 EUROPE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 16 EUROPE OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 17 EUROPE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 18 EUROPE BIVALIRUDIN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 19 EUROPE DABIGATRAN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 20 EUROPE EDOXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 21 EUROPE BETRIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 22 EUROPE RIVAROXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 23 EUROPE APIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 24 EUROPE ENOXAPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 EUROPE DALTEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 26 EUROPE OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 27 EUROPE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION , 2017-2026 (USD MILLION)

TABLE 28 EUROPE ORAL IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 29 EUROPE INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 30 EUROPE INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 31 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 32 EUROPE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 EUROPE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 34 EUROPE ONCOLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 35 EUROPE RESPIRATORY IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 36 EUROPE NEPHROLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 37 EUROPE CNS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 38 EUROPE OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 39 EUROPE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 40 EUROPE PRE-SURGICAL PROCEDURES IN EUROPE ANTICOAGULATION THERAPY MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 41 EUROPE POST-SURGICAL PROCEDURES IN EUROPE ANTICOAGULATION THERAPY MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 42 EUROPE KIDNEY DIALYSIS IN EUROPE ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 EUROPE HEART VALVE REPLACEMENT IN EUROPE ANTICOAGULATION THERAPY MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 44 EUROPE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 45 EUROPE GENERICS IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 46 EUROPE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 47 EUROPE BRANDED IN EUROPE ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 48 EUROPE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 EUROPE HOSPITALS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 50 EUROPE CLINICS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 51 EUROPE HOMECARE IN ANTICOAGULATION THERAPY MARKET,BY REGION,  2017-2026 (USD MILLION)

TABLE 52 EUROPE AMBULATORY SURGICAL CENTERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 53 EUROPE OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 54 EUROPE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 55 EUROPE HOSPITAL PHARMACY IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 56 RETAIL PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 57 EUROPE ONLINE PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 58 EUROPE ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 59 EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 60 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 61 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 62 EUROPE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 63 EUROPE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 64 EUROPE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 65 EUROPE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 66 EUROPE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 67 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 68 EUROPE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 69 EUROPE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 70 EUROPE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 71 EUROPE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION))

TABLE 72 EUROPE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 73 EUROPE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 74 GERMANY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 75 GERMANY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 76 GERMANY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 77 GERMANY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 78 GERMANY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 79 GERMANY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 80 GERMANY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 81 GERMANY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 82 GERMANY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 83 GERMANY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 84 GERMANY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE,  2017-2026 (USD MILLION)

TABLE 85 GERMANY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 86 GERMANY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 87 GERMANY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 88 GERMANY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 89 FRANCE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 90 FRANCE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 91 FRANCE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 92 FRANCE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 93 FRANCE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 94 FRANCE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 95 FRANCE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 96 FRANCE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 97 FRANCE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 98 FRANCE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 99 FRANCE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 100 FRANCE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 101 FRANCE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 102 FRANCE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 103 FRANCE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 104 ITALY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 105 ITALY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 106 ITALY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 107 ITALY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 108 ITALY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 109 ITALY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 110 ITALY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 111 ITALY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 112 ITALY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 113 ITALY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 114 ITALY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 115 ITALY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 116 ITALY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 117 ITALY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 118 ITALY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 119 U.K. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 120 U.K. ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 121 U.K. NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 122 U.K. HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 123 U.K. VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 124 U.K. ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 125 U.K. ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 126 U.K. INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 127 U.K. ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 128 U.K. CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 129 U.K. ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 130 U.K. ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 131 U.K. BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 132 U.K. ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 133 U.K. ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 134 SPAIN ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 135 SPAIN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 136 SPAIN NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 137 SPAIN HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 138 SPAIN VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 139 SPAIN ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 140 SPAIN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 141 SPAIN INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 142 SPAIN ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 143 SPAIN CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 144 SPAIN ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 145 SPAIN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 146 SPAIN BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 147 SPAIN ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 148 SPAIN ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 149 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY TREATMENT,  2017-2026 (USD MILLION)

TABLE 150 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 151 SWITZERLAND NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 152 SWITZERLAND HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 153 SWITZERLAND VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 154 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE,  2017-2026 (USD MILLION)

TABLE 155 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 156 SWITZERLAND INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 157 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 158 SWITZERLAND CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 159 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY PROCEDURE,  2017-2026 (USD MILLION)

TABLE 160 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 161 SWITZERLAND BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 162 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY END USER,  2017-2026 (USD MILLION)

TABLE 163 SWITZERLAND ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 164 RUSSIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 165 RUSSIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 166 RUSSIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 167 RUSSIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 168 RUSSIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 169 RUSSIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 170 RUSSIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 171 RUSSIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 172 RUSSIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 173 RUSSIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 174 RUSSIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 175 RUSSIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 176 RUSSIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 177 RUSSIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 178 RUSSIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 179 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 180 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 181 NETHERLANDS NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 182 NETHERLANDS HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 183 NETHERLANDS VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 184 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 185 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 186 NETHERLANDS INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 187 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 188 NETHERLANDS CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 189 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY PROCEDURE,  2017-2026 (USD MILLION)

TABLE 190 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 191 NETHERLANDS BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 192 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY END USER,  2017-2026 (USD MILLION)

TABLE 193 NETHERLANDS ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 194 BELGIUM ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 195 BELGIUM ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 196 BELGIUM NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 197 BELGIUM HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 198 BELGIUM VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 199 BELGIUM ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 200 BELGIUM ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 201 BELGIUM INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 202 BELGIUM ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 203 BELGIUM CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 204 BELGIUM ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 205 BELGIUM ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 206 BELGIUM BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 207 BELGIUM ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 208 BELGIUM ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 209 TURKEY ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 210 TURKEY ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS,  2017-2026 (USD MILLION)

TABLE 211 TURKEY NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 212 TURKEY HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 213 TURKEY VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 214 TURKEY ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 215 TURKEY ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 216 TURKEY INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 217 TURKEY ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA,  2017-2026 (USD MILLION)

TABLE 218 TURKEY CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET,  BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 219 TURKEY ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 220 TURKEY ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 221 TURKEY BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 222 TURKEY ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 223 TURKEY ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL,  2017-2026 (USD MILLION)

TABLE 224 REST OF EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT,  2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions